Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/F2RL1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/F2RL1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/F2RL1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/F2RL1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00329566 | Stomach | GC | regulation of actin cytoskeleton organization | 48/1159 | 358/18723 | 3.57e-07 | 1.88e-05 | 48 |
GO:00420606 | Stomach | GC | wound healing | 52/1159 | 422/18723 | 1.63e-06 | 7.50e-05 | 52 |
GO:0071356 | Stomach | GC | cellular response to tumor necrosis factor | 34/1159 | 229/18723 | 1.85e-06 | 8.24e-05 | 34 |
GO:19029056 | Stomach | GC | positive regulation of supramolecular fiber organization | 32/1159 | 209/18723 | 1.88e-06 | 8.30e-05 | 32 |
GO:20003796 | Stomach | GC | positive regulation of reactive oxygen species metabolic process | 17/1159 | 76/18723 | 3.01e-06 | 1.25e-04 | 17 |
GO:00444036 | Stomach | GC | biological process involved in symbiotic interaction | 39/1159 | 290/18723 | 4.07e-06 | 1.63e-04 | 39 |
GO:0034612 | Stomach | GC | response to tumor necrosis factor | 35/1159 | 253/18723 | 6.68e-06 | 2.54e-04 | 35 |
GO:0030595 | Stomach | GC | leukocyte chemotaxis | 32/1159 | 230/18723 | 1.45e-05 | 4.68e-04 | 32 |
GO:0050900 | Stomach | GC | leukocyte migration | 44/1159 | 369/18723 | 2.30e-05 | 6.81e-04 | 44 |
GO:00081546 | Stomach | GC | actin polymerization or depolymerization | 30/1159 | 218/18723 | 3.29e-05 | 8.94e-04 | 30 |
GO:19030346 | Stomach | GC | regulation of response to wounding | 25/1159 | 167/18723 | 3.58e-05 | 9.46e-04 | 25 |
GO:19049516 | Stomach | GC | positive regulation of establishment of protein localization | 39/1159 | 319/18723 | 3.79e-05 | 9.76e-04 | 39 |
GO:00020646 | Stomach | GC | epithelial cell development | 30/1159 | 220/18723 | 3.92e-05 | 9.90e-04 | 30 |
GO:0042110 | Stomach | GC | T cell activation | 53/1159 | 487/18723 | 4.56e-05 | 1.10e-03 | 53 |
GO:00716925 | Stomach | GC | protein localization to extracellular region | 43/1159 | 368/18723 | 4.61e-05 | 1.11e-03 | 43 |
GO:00093065 | Stomach | GC | protein secretion | 42/1159 | 359/18723 | 5.46e-05 | 1.29e-03 | 42 |
GO:00325355 | Stomach | GC | regulation of cellular component size | 44/1159 | 383/18723 | 5.66e-05 | 1.31e-03 | 44 |
GO:00355925 | Stomach | GC | establishment of protein localization to extracellular region | 42/1159 | 360/18723 | 5.82e-05 | 1.34e-03 | 42 |
GO:00514956 | Stomach | GC | positive regulation of cytoskeleton organization | 30/1159 | 226/18723 | 6.50e-05 | 1.46e-03 | 30 |
GO:0002696 | Stomach | GC | positive regulation of leukocyte activation | 46/1159 | 409/18723 | 6.50e-05 | 1.46e-03 | 46 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F2RL1 | SNV | Missense_Mutation | rs185549069 | c.308N>A | p.Arg103Gln | p.R103Q | P55085 | protein_coding | deleterious(0.04) | benign(0.103) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.946A>T | p.Ser316Cys | p.S316C | P55085 | protein_coding | tolerated(0.05) | possibly_damaging(0.882) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
F2RL1 | insertion | Nonsense_Mutation | novel | c.703_704insCACATAAGTTAGCATAACATGCTAA | p.Leu235SerfsTer6 | p.L235Sfs*6 | P55085 | protein_coding | | | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F2RL1 | insertion | Frame_Shift_Ins | novel | c.947_948insAAATATTGATCTCTACATCCCCCAACACTCCA | p.Ser316ArgfsTer24 | p.S316Rfs*24 | P55085 | protein_coding | | | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1076T>C | p.Leu359Pro | p.L359P | P55085 | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
F2RL1 | SNV | Missense_Mutation | novel | c.998N>G | p.Ser333Cys | p.S333C | P55085 | protein_coding | deleterious(0.03) | probably_damaging(0.967) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
F2RL1 | SNV | Missense_Mutation | novel | c.945N>C | p.Lys315Asn | p.K315N | P55085 | protein_coding | tolerated(0.26) | probably_damaging(0.913) | TCGA-EA-A97N-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1018N>A | p.Asp340Asn | p.D340N | P55085 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
F2RL1 | SNV | Missense_Mutation | novel | c.1019N>G | p.Asp340Gly | p.D340G | P55085 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F2RL1 | SNV | Missense_Mutation | | c.376N>G | p.Ile126Val | p.I126V | P55085 | protein_coding | tolerated(0.34) | benign(0.012) | TCGA-AP-A054-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | ERYTHROMYCIN | ERYTHROMYCIN | 18212111 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | AC-55541 | CHEMBL493076 | 18720984 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178100874 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | | ROXITHROMYCIN | ROXITHROMYCIN | 18212111 |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 381744949 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178103272 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 178103271 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178100746 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | agonist | 178103269 | | |
2150 | F2RL1 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME | antagonist | 178103270 | | |